News & Updates

Back to All News

Concomitant antiplatelet agents increased bleeding events in atrial fibrillation/vascular disease patients

May 30, 2019 Research News

By Donna Loyle, communications specialist, LIMR

While most patients diagnosed with a combination of atrial fibrillation (AF) and vascular disease are treated with oral anticoagulants, concomitant antiplatelet therapy for various indications also may be administered. However, combination therapy is associated with increased risk for bleeding and may not be associated with improved cardiovascular outcomes depending on the indication, according to the results of a nationwide study in which Main Line Health participated.

Researchers analyzed treatments and outcomes in 1,920 patients diagnosed with both new-onset AF and vascular disease who were part of the ORBIT-AF II patient registry, a Duke University initiative funded by a grant from Johnson & Johnson. Main Line Health’s Peter Kowey, MD, and Michael Ezekowitz, DPhil, were members of the steering committee for this registry that has enrolled more than 20,000 patients who were diagnosed with AF and are receiving an anticoagulant drug.

When looking at treatment outcomes, the researchers found that patients with AF and vascular disease do indeed have an increased risk for major adverse cardiovascular and neurological events (MACNE). Consequently, most of the patients in this cohort were treated with oral anticoagulants, either a direct-acting anticoagulant (DOAC) or vitamin K antagonist.

About half of the patients in this cohort also were being treated with concomitant antiplatelet therapy. Although some had reason to take antiplatelet drugs, many did not. That percentage has been increasing in recent years, even though this treatment approach is inconsistent with consensus recommendations in terms of indication and duration, noted the researchers.

“The most significant finding of our study was that treatment with both DOACs and antiplatelet therapy led to more bleeding events in this subset of patients,” noted Kowey, chairman emeritus of cardiology at Lankenau Heart Institute, professor at the Lankenau Institute for Medical Research, and one of the study’s authors. “Compounding this dilemma, we did not see any definitive improvements in MACNE in these patients, so we are cautioning clinicians to reconsider concomitant use of antiplatelet agents in these cases. Specifically, when seeing an anticoagulated patient who is also on aspirin and/or a thienopyridine, ask the question: ‘Does my patient need all of these drugs, and if so, when can any of them be stopped?’” 

Dr. Kowey and his coauthors called for further studies to clarify the optimal management of this specific high-risk population.

The study’s results were published in the manuscript “Treatment of Atrial Fibrillation with Concomitant Coronary or Peripheral Artery Disease: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II” in American Heart Journal. The full manuscript is available here: https://bit.ly/2Mc58m3

About Lankenau Institute for Medical Research

Lankenau Institute for Medical Research (LIMR) is a nonprofit biomedical research institute located on the campus of Lankenau Medical Center and is part of Main Line Health. Founded in 1927, LIMR’s mission is to improve human health and well-being. Faculty and staff are devoted to advancing innovative new approaches to formidable medical challenges, including cancer, cardiovascular disease, gastrointestinal disorders and autoimmune diseases, such as diabetes and arthritis. LIMR’s principal investigators conduct basic, preclinical and translational research, using their findings to explore ways to improve disease detection, diagnosis, treatment and prevention. They are committed to extending the boundaries of human health through technology transfer and training of the next generation of scientists and physicians.